Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics, Inc. (Nasdaq: PSTV) will release its third quarter 2020 financial results on October 22, 2020, after market close. A conference call will follow at 5:00 p.m. ET for management to discuss these results and provide corporate updates. The call will include a live webcast and can be accessed through their official IR page. Plus Therapeutics focuses on developing nanoliposome-encapsulated radionuclides targeted at rare cancers, aiming to enhance patient treatment through innovative drug delivery methods.
Plus Therapeutics, Inc. (Nasdaq: PSTV) has appointed five experts to its Clinical Advisory Board to enhance its efforts in developing nanoscale radiotherapeutics for rare brain cancers. The new members include leaders in neurological surgery and neuro-oncology from prestigious institutions. CEO Marc H. Hedrick emphasized the importance of their expertise in navigating clinical challenges, particularly for glioblastoma patients. Plus Therapeutics focuses on innovative drug delivery mechanisms, aiming to improve treatment efficacy and safety for patients.
Plus Therapeutics (Nasdaq: PSTV) announced its participation in the 22nd H. C. Wainwright Annual Global Investment Conference from September 14-16, 2020. The Company is scheduled to present on September 15 at 4:00 p.m. ET, with one-on-one meetings available during the event. The presentation will be live-streamed and accessible for later viewing. Plus Therapeutics focuses on developing innovative drug delivery systems targeting rare cancers, utilizing a unique nanotechnology platform to enhance treatment safety and efficacy. More details can be found on their corporate website.
Plus Therapeutics (Nasdaq: PSTV) announced its invitation to present at the 9th Annual Gateway Conference, scheduled for September 9-10, 2020. The management will present on September 10 at 3:30 p.m. ET. A live webcast of the presentation will be available for replay. Interested parties can schedule one-on-one meetings during the conference by contacting conference@gatewayir.com.
This conference connects compelling companies with top institutional investors, aimed at enhancing investor relations.
Plus Therapeutics, Inc. (PSTV) announced its participation in the LD 500 investor conference on September 4, 2020, at 10:20 AM ET. Dr. Marc Hedrick, the company's President and CEO, will present and engage in a Q&A session with investors. The conference occurs from September 1-4 and aims to provide a virtual platform for exposure to unique companies amid the COVID-19 pandemic. LD Micro's founder, Chris Lahiji, emphasizes accessibility for all participants. For more details, visit Plus Therapeutics' profile and register for the event.
Plus Therapeutics, Inc. (Nasdaq: PSTV) reported a Q2 2020 net loss of $1.8 million, or $0.45 per share, significantly reduced from a loss of $9.1 million, or $20.67 per share, in Q2 2019. The company ended the quarter with $9.3 million in cash. Key developments include ongoing clinical trials for Rhenium NanoLiposomes (RNL™) aimed at treating recurrent glioblastoma, with preliminary data expected soon. The firm plans to finalize its Phase 2 trial plan and seek Orphan Drug Designation while exploring partnerships for its oncology portfolio.
Plus Therapeutics (Nasdaq: PSTV) will release its Second Quarter Fiscal Year 2020 financial results after market close on August 10, 2020. A conference call at 5:00 PM ET will provide insights into the results and a business update. The company focuses on developing radiotherapeutics using its nanotechnology platform to target rare cancers. This technology enhances drug delivery and formulation for improved patient safety and convenience.
Plus Therapeutics (Nasdaq: PSTV) announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial, evaluating Rhenium NanoLiposomes (RNL™) in adults with recurrent glioblastoma (GBM). The trial has expanded to a second site at UT Southwestern Medical Center, enrolling 15 patients across five cohorts, with six more planned. RNL aims to deliver radiation doses up to 25 times greater than conventional methods, with further developments anticipated including cohort 6, completion of enrollment, and potential orphan drug designations.
Plus Therapeutics (PSTV) announced its participation in the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day, scheduled for July 30, 2020, at 10:00 p.m. EST. Dr. Marc Hedrick will lead the presentation and engage with investors during the session. Attendees can register for free tickets to join the live event or opt for a Video on Demand Ticket. A replay will be available on the company's website a week later for those unable to attend live. Plus Therapeutics specializes in developing radiotherapeutics targeting rare cancers using a unique nanotechnology platform.
On July 6, 2020, Plus Therapeutics, Inc. (PSTV) announced the approval of stock options for key executives. Dr. Gregory Stein was granted options for 40,000 shares at an exercise price of $2.11, and Andrew Sims received the same number at $2.23, both vesting over four years. This decision aligns with the company's 2015 New Employee Incentive Plan, which was recently amended to allow additional shares for inducement awards. Plus Therapeutics is focused on developing innovative cancer therapies.